Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Depreciation & Amortization (CF) (2019 - 2025)

Historic Depreciation & Amortization (CF) for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $2.1 million.

  • Nurix Therapeutics' Depreciation & Amortization (CF) fell 1683.01% to $2.1 million in Q4 2025 from the same period last year, while for Nov 2025 it was $8.7 million, marking a year-over-year decrease of 620.3%. This contributed to the annual value of $8.7 million for FY2025, which is 620.3% down from last year.
  • As of Q4 2025, Nurix Therapeutics' Depreciation & Amortization (CF) stood at $2.1 million, which was down 1683.01% from $2.0 million recorded in Q3 2025.
  • In the past 5 years, Nurix Therapeutics' Depreciation & Amortization (CF) ranged from a high of $2.5 million in Q4 2024 and a low of $600000.0 during Q2 2021
  • Its 5-year average for Depreciation & Amortization (CF) is $1.7 million, with a median of $1.9 million in 2023.
  • Per our database at Business Quant, Nurix Therapeutics' Depreciation & Amortization (CF) soared by 11666.67% in 2022 and then crashed by 1683.01% in 2025.
  • Quarter analysis of 5 years shows Nurix Therapeutics' Depreciation & Amortization (CF) stood at $767000.0 in 2021, then skyrocketed by 111.08% to $1.6 million in 2022, then grew by 19.46% to $1.9 million in 2023, then surged by 31.8% to $2.5 million in 2024, then dropped by 16.83% to $2.1 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $2.1 million for Q4 2025, versus $2.0 million for Q3 2025 and $2.2 million for Q2 2025.